消癌平联合卡瑞利珠单抗对晚期食管癌血VEGF及肿瘤标志物的影响

The effect of Xiaoaiping combined with camrelizumab on serum VEGF and tumor markers in advanced esophageal cancer

目的探索食管癌晚期患者采用消癌平和卡瑞利珠单抗联合治疗后血管内皮生长因子(vascular endothelial growth factor,VEGF)及肿瘤标志物的情况。方法选取于2020年3月至2022年3月在广西医科大学第一附属医院和广西中医药大学附属国际壮医医院接受治疗的43例食管癌晚期患者,根据随机数字表法分为对照组和联合治疗组。两组患者均使用卡瑞利珠单抗免疫疗法,此外联合治疗组患者还辅助使用消癌平注射液进行治疗,疗程直至进展。检测两组患者第1周期、第3周期、第6周期、第9周期及第17周期的VEGF、肿瘤标志物水平。结果两组患者在治疗前、治疗后第1周期及第3周期的VEGF、糖类抗原125(carbohydrate antigen 125,CA125)、糖类抗原199(carbohydrate antigen 199,CA199)、癌胚抗原(carcinoembryonic antigen,CEA)水平差异无统计学意义(P>0.05);第6周期两组患者的CA125、CA199、VEGF水平差异无统计学意义(P>0.05),两组患者的CEA水平差异有统计学意义(P<0.05);第9周期、第17周期联合治疗组患者的VEGF、CA125、CA199、CEA水平均明显低于对照组,差异有统计学意义(P<0.05)。结论消癌平和卡瑞利珠单抗联合治疗对食管癌晚期患者具有良好的临床效果,可降低患者体内的VEGF及肿瘤标志物水平。

Objective To explore the effects of Xiaoaiping and camrelizumab on vascular endothelial growth factor(VEGF)and tumor markers in patients with advanced esophageal cancer.Methods A total of 43 patients with advanced esophageal cancer who were treated in the First Affiliated Hospital of Guangxi Medical University and Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine from March 2020 to March 2022 were selected and divided into control group and combined treatment group according to the random number table method.Both groups were treated with camrelizumab immunotherapy,and the patients in combined treatment group were also treated with Xiaoaiping injection until disease progression.The levels of VEGF and tumor markers in two groups were detected after the first cycle,the third cycle,the sixth cycle,the ninth cycle and the seventeenth cycle of treatment.Results The levels of VEGF,carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)in the first cycle and the third cycle in two groups had no significant difference before and after treatment(P>0.05);There was no significant difference in CA125,CA199 and VEGF levels between two groups in the 6th cycle(P>0.05);There was a significant difference in CEA level between two groups(P<0.05);The levels of VEGF,CA125,CA199 and CEA in combined treatment group were significantly lower than those in control group at the 9th cycle and the 17th cycle(P<0.05).Conclusion Xiaoaiping combined with camrelizumab has a good clinical effect on patients with advanced esophageal cancer,which can reduce the levels of VEGF and tumor markers in patients.